At Alimentiv Clinical Trials, we constantly strive to provide safer and more non-invasive methods for disease activity assessment. We offer our clients Magnetic Resonance Imaging (MRI) / Enterography (MRE) as a non-invasive imaging option. MRE has high diagnostic accuracy, does not require exposure to ionizing radiation, and is considerably less invasive than endoscopy, making it an ideal option for serial assessments in clinical trials.


  • Perianal Fistulizing Crohn’s Disease
  • Small Bowel Crohn’s Disease
  • Fibrostenotic Crohn’s Disease

Scoring Indices:

  • Van Assche
  • Magnetic Resonance Index of Activity (MaRIA) Scoring System
  • Magnifi-CD
  • Constrict Score
  • Stricturing Radiology Index (SRI)

In addition to MRE, we are also excited to announce our partnership with the International Bowel Ultrasound (IBUS) Group e.V. to offer Intestinal Ultrasound (IUS) central reading services in clinical trials of adults and children with Inflammatory Bowel Disease (IBD).

IUS is a cost-effective, tolerable, and repeatable non-invasive monitoring tool that has shown great accuracy in assessing IBD disease activity and complications. It may also detect early treatment responses that routine colonoscopy cannot identify.

This partnership aims to deliver synergistic value to IBD research by combining our clinical trial design expertise and intestinal ultrasound. Our partnership with IBUS will help to advance knowledge and experience in the field of IUS for patients with IBD, and the implementation of IBUS ultrasound central reading services in Alimentiv sponsor-funded IBD clinical trials is expected to be available in 2023.

Trust in our non-invasive imaging options to provide accurate and safe assessments of disease activity in your clinical trial.